Prelude Therapeutics (PRLD) Earnings Date, Estimates & Call Transcripts $0.90 +0.02 (+1.96%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Prelude Therapeutics Earnings Summary Upcoming Earnings DateMay. 6Before Market OpensEstimatedConsensus EPS (Mar. 10) -$0.49 Actual EPS (Mar. 10) -$0.38 Beat By $0.11 Actual Revenue (Mar. 10) $4.00MPrelude Therapeutics announced Q4 2024 earnings on March 10, 2025, reporting an EPS of -$0.38, which topped the consensus estimate of -$0.49 by $0.11. Quarterly revenue was reported to be $4 million. With a trailing EPS of -$1.69, Prelude Therapeutics' earnings are expected to remain at ($1.81) per share in the coming year. Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Press Release (8-K) Annual Report (10-K)PRLD Upcoming EarningsPrelude Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Prelude Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPRLD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PRLD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Prelude Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.47-$0.47-$0.47Q2 20251-$0.48-$0.48-$0.48Q3 20251-$0.49-$0.49-$0.49Q4 20251-$0.50-$0.50-$0.50FY 20254($1.94)($1.94)($1.94) Prelude Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/6/2025(Estimated)--------3/10/2025Q4 2024-$0.49-$0.38+$0.11-$0.38-$4.00M11/6/2024--$0.48-$0.43+$0.05-$0.43-$3.00M8/12/2024--$0.46-$0.46--$0.46--5/7/2024Q1 2024-$0.47-$0.42+$0.05-$0.42--2/15/2024Q4 2023-$0.50-$0.47+$0.03-$0.47--11/1/2023Q3 2023-$0.58-$0.45+$0.13-$0.45--8/3/2023Q2 2023-$0.65-$0.54+$0.11-$0.54--5/8/2023Q1 2023-$0.68-$0.58+$0.10-$0.58-- Prelude Therapeutics Earnings - Frequently Asked Questions When is Prelude Therapeutics's earnings date? Prelude Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on PRLD's earnings history. Did Prelude Therapeutics beat their earnings estimates last quarter? In the previous quarter, Prelude Therapeutics (NASDAQ:PRLD) reported ($0.38) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.49) by $0.11. Learn more on analysts' earnings estimate vs. PRLD's actual earnings. How much revenue does Prelude Therapeutics generate each year? Prelude Therapeutics (NASDAQ:PRLD) has a recorded annual revenue of $7 million. How much profit does Prelude Therapeutics generate each year? Prelude Therapeutics (NASDAQ:PRLD) has a recorded net income of -$121.83 million. PRLD has generated -$1.69 earnings per share over the last four quarters. What is Prelude Therapeutics's EPS forecast for next year? Prelude Therapeutics's earnings are expected to stay at ($1.81) per share in the next year. More Earnings Resources from MarketBeat Related Companies Neurogene Earnings Date Eledon Pharmaceuticals Earnings Date Voyager Therapeutics Earnings Date Kodiak Sciences Earnings Date Canopy Growth Earnings Date Esperion Therapeutics Earnings Date INmune Bio Earnings Date Inhibrx Earnings Date Actuate Therapeutics Earnings Date Cybin Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings This page (NASDAQ:PRLD) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRLD Stock Free PRLD Stock Alerts